Assess the Outcomes of Transcatheter Aortic Valve Replacement in Bicuspid Valve with Mixed Disease versus Predominant Aortic Stenosis

DOI: https://doi.org/10.2147/cia.s447272

IF: 3.829

2024-05-01

Clinical Interventions in Aging

Abstract:Changjin Wang, 1, &ast Xiaolu Hu, 1, 2, &ast Songyuan Luo, 1, &ast Yinghao Sun, 1 Bangyuan Yang, 1 Shengneng Zheng, 3 Jiaohua Chen, 1 Ming Fu, 1 Ruixin Fan, 4 Jie Li, 1 Jianfang Luo 1, 2 1 Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; 2 School of Medicine South China University of Technology, Guangzhou, People's Republic of China; 3 Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; 4 Department of Cardiac Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Li; Jianfang Luo, Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, &num96 Dongchuan Road, Yuexiu District, Guangzhou, Guangdong, 510080, People's Republic of China, Tel +86-20-83827812, Fax +86-20-83875453, Email ; Purpose: In mixed aortic valve disease (MAVD), the results of transcatheter aortic valve replacement (TAVR) are conflicting. There is limited data on the outcomes of TAVR in patients with bicuspid aortic valve (BAV) and MAVD. The objective of this study is to compare outcomes after TAVR in BAV patients with MAVD and predominant aortic stenosis (PAS). Patients and Methods: Patients with BAV who underwent TAVR between January 2016 and April 2023 were included. The primary outcome was device success. The secondary endpoints were periprocedural mortality and other complications as defined by the Valve Academic Research Consortium-3 (VARC-3). Propensity score matching was used to minimize potential confounding. Results: A total of 262 patients were included in this study, 83 of whom had MAVD. The median age was 72 years, and 55.7% were male. The baseline comorbidity risk files were comparable between the two groups. Patients with MAVD had more mitral regurgitation, tricuspid regurgitation and pulmonary hypertension, larger annular and left ventricular outflow tract dimensions, and more severe calcification than PAS. In the unmatched population, MAVD patients had similar device success rate (69.9% vs 79.9%, P =0.075) and 30-day mortality (3.6% vs 3.4%, P =1) compared to PAS. Propensity score matching resulted in 66 patient pairs. Device success rate were still comparable in the matched population. Other clinical outcomes, including stroke, bleeding (type 2– 4), major vascular complications, acute kidney injury (stage 2– 4) and permanent pacemaker implantation, were comparable between the two groups. Multivariable logistic regression analysis did not show MAVD to be an independent negative predictor of device success. At one year, survival was similar between patients with MAVD and those with PAS. Conclusion: For the bicuspid valve, patients with MAVD had a more challenging anatomy. MAVD patients associated with comparable 30-day clinical outcomes after TAVR compared to PAS patients in patients with BAV. Keywords: transcatheter aortic valve replacement, mixed aortic valve disease, bicuspid aortic valve, device success, propensity score match The indications for transcatheter aortic valve replacement (TAVR) have been expanded from a high surgical risk to a low surgical risk. 1–3 The trend towards TAVR in younger and lower-risk patients has led to an increase in the number of BAV patients encountered by cardiac teams. 4 In previous studies, the outcome of TAVR in patients with BAV was comparable to that in patients with tricuspid valve. 5,6 Mixed aortic valve disease (MAVD), a combination of AS and moderate or severe aortic regurgitation (AR), was not uncommon in practice. 7 Moderate to severe AR was observed in 3% to 15% of patients with BAV treated with TAVR. 5,8 Due to pressure and volume overload, MAVD is more aggressive than isolated aortic valve lesions and is associated with worse clinical outcomes. 9,10 MAVD is currently managed according to the predominant lesion and the underlying surgical risk. 11,12 However, in patients with MAVD, the results of TAVR were mixed. 13–16 In a retrospective study analysing 1133 patients (MAVD, n=688), patients with MAVD who underwent TAVR had a lower 3-year mortality rate compared with patients with AS al -Abstract Truncated-

geriatrics & gerontology,gerontology